Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HIV-1 envelope glycoprotein trimer is the only viral protein on the surface of the HIV-1 virion. It is a trimer of gp120-gp41 heterodimers, heavily glycosylated, and responsible for both recognition of host CD4 and chemokine (CCR5/CXCR4) receptors and for catalyzing the fusion of viral and host membranes, enabling entry of the virus into target cells. Env undergoes dramatic conformational changes upon receptor binding, triggering the fusion process. Its strong sequence variability and dense glycan shield complicate vaccine design and therapeutic targeting, but it is the sole specific target for broadly neutralizing anti-HIV antibodies, making it central to both immunological research and clinical development in HIV/AIDS
Inhibition of Env-mediated membrane fusion (fusion inhibitors)\nNeutralization of Env’s ability to bind CD4 and co-receptors (monoclonal antibodies)\nSteric blockade or stabilization of pre-fusion conformations
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HIV-1 envelope glycoprotein trimer (HIV-1 Env trimer).